AKBLF (Alk-Abello AS) Loans Receivable : $0.0 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Alk-Abello AS Loans Receivable?

Alk-Abello AS's Loans Receivable for the quarter that ended in Dec. 2024 was $0.0 Mil.

Alk-Abello AS Loans Receivable Historical Data

The historical data trend for Alk-Abello AS's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Loans Receivable Chart

Alk-Abello AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Loans Receivable

Get a 7-Day Free Trial

Alk-Abello AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Loans Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Alk-Abello AS Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Alk-Abello AS Loans Receivable Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Alk-Abello AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (OTCPK:AKBLF) » Definitions » Loans Receivable

Comparable Companies

Traded in Other Exchanges

ALKBc:UK 0OIR:UK ALK B:Denmark 4AJ0:Germany

Address

Boge Alle 6-8, Horsholm, DNK, DK-2970

Website

https://www.alk.net

Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.